Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines.

Theyer G, Schirmböck M, Thalhammer T, Sherwood ER, Baumgartner G, Hamilton G
J Urol. 1993 150 (5 Pt 1): 1544-7

PMID: 8105110 · DOI:10.1016/s0022-5347(17)35838-x

The treatment of advanced metastatic prostate cancer by hormone manipulation or orchiectomy is frequently followed by the appearance of hormone-insensitive and highly chemoresistant tumor cells. In this study we have investigated the contribution of the P-glycoprotein-mediated drug efflux (multidrug-resistance; MDR) to the cellular resistance of prostate carcinoma-derived cell lines to diverse cytotoxic drugs by detection of P-glycoprotein (P-gp) measurement of P-gp-mediated drug transport and reversal of MDR by chemosensitizers. The in vitro chemosensitivity of three prostate cancer cell lines (PC-3, DU-145 and LNCaP) to doxorubicin was measured in a thymidine incorporation proliferation assay. Growth of the partially hormone-sensitive cell line LNCaP is inhibited by low doses of doxorubicin (IC50:27 ng./ml.), but PC-3 and DU-145 are highly resistant to the drug, with IC50 values of 10 micrograms./ml. and 7.5 micrograms./ml., respectively. The chemosensitivity of the PC-3 and DU-145 cells is increased in response to 1 microM. verapamil, 1 micrograms./ml. cyclosporine A and 2 microM. tamoxifen, which are known to partially reverse the MDR phenotype in other resistant tumors. A verapamil-sensitive drug efflux has been demonstrated for the PC-3 and Du-145, but not for the LNCaP, cell lines, using flow cytometric measurements of the P-gp substrate rhodamine 123 efflux from preloaded cells. In agreement with the functional measurements, the expression of the P-glycoprotein was detected in the PC-3 and Du-145 cell lines in Western blots using the monoclonal C 219 antibody. In conclusion, the chemoresistant and hormone-insensitive PC-3 and Du-145 cell lines express P-gp and exhibit verapamil-sensitive drug efflux, indicative of MDR. However, the low MDR-reversal rates observed in these cell lines in response to chemosensitizers in clinically achievable concentrations (approximately 2- to 3-fold reversal), point to non-MDR-associated cellular mechanisms as dominant factors of chemoresistance in prostate cancer.

MeSH Terms (19)

Adenocarcinoma Antimetabolites, Antineoplastic Antineoplastic Agents ATP Binding Cassette Transporter, Subfamily B, Member 1 Carrier Proteins Cell Division Cyclosporine Doxorubicin Drug Resistance Humans Male Membrane Glycoproteins Phenotype Prostatic Neoplasms Rhodamine 123 Rhodamines Tamoxifen Tumor Cells, Cultured Verapamil

Connections (1)

This publication is referenced by other Labnodes entities:

Links